Literature DB >> 10638623

Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.

S Nakai, T Masaki, K Kurokohchi, A Deguchi, M Nishioka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10638623     DOI： 10.1111/j.1572-0241.2000.01667.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  26 in total

1.  Fenofibrate-induced liver injury.

Authors:  Kazufumi Dohmen; Chun Yang Wen; Shinya Nagaoka; Koji Yano; Seigo Abiru; Toshihito Ueki; Atsumasa Komori; Manabu Daikoku; Hiroshi Yatsuhashi; Hiromi Ishibashi
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

2.  Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.

Authors:  Cynthia Levy; Keith D. Lindor
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

3.  Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.

Authors:  Atsushi Tanaka; Junko Hirohara; Yasuni Nakanuma; Hirohito Tsubouchi; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2014-09-20       Impact factor: 7.527

Review 4.  New therapies for primary biliary cirrhosis.

Authors:  Annarosa Floreani; Irene Franceschet; Lisa Perini; Nora Cazzagon; M Eric Gershwin; Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 5.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

6.  Fenofibrate in primary biliary cirrhosis: a pilot study.

Authors:  E N Liberopoulos; M Florentin; M S Elisaf; D P Mikhailidis; E Tsianos
Journal:  Open Cardiovasc Med J       Date:  2010-04-28

Review 7.  Nuclear receptors as therapeutic targets in cholestatic liver diseases.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

8.  Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.

Authors:  Nisanne S Ghonem; James L Boyer
Journal:  Hepatology       Date:  2013-04-05       Impact factor: 17.425

9.  Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.

Authors:  Anna Reig; Pilar Sesé; Albert Parés
Journal:  Am J Gastroenterol       Date:  2017-10-10       Impact factor: 10.864

10.  Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

Authors:  Kazufumi Dohmen; Toshihiko Mizuta; Makoto Nakamuta; Naoya Shimohashi; Hiromi Ishibashi; Kyosuke Yamamoto
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.